Adaptive Biotechnologies Announces New Data Demonstrating the Benefit of Serial MRD Testing ...

Analysis of the MASTER trial (Abstract 481) showed clonoSEQ’s ability to measure deep and durable responses and permit treatment discontinuation in multiple myeloma patients Data in more than 30 abstracts

Related Keywords

Montana ,United States ,American ,Carrie Mendivil ,Lance Baldo ,Karina Calzadilla ,Erica Schmitt ,Exchange Commission ,American Society Of Hematology ,Koch Industries ,Adaptive Biotechnologies Corporation Nasdaq ,Gilmartin Group ,Biotechnologies Corporation ,American Society ,Annual Meeting ,Autologous Transplantation ,Adapted Consolidation ,Final Primary Endpoint Analysis ,Chief Medical Officer ,Adaptive Biotechnologies ,Forward Looking Statements This ,Financial Condition ,Vice President ,Investor Relations ,New Murdoch ,Money ,Ational ,